Gastric Cancer Treatment Market to Expand Rapidly to $4.4 Billion by 2024
December 22, 2015.
The treatment market for gastric and gastroesophageal junction adenocarcinoma (gastric cancer) will experience rapid growth, from $1.13 billion in 2014 to $4.39 billion by 2024, representing CAGR of 14.6%, according to GlobalData.
The company’s latest report states that the rise will be driven primarily by the introduction of premium-priced therapies for advanced gastric cancer and, as a consequence, the increased uptake of therapy and lengthier treatment duration.
GlobalData analyst Fenix Leung says that growth will be strongest across the five major European markets, as sales will increase from $301 million in 2014 to $1.49 billion by 2024, at a robust CAGR of 17.3%.
Leung notes that “Roche is expected to remain a strong player in the gastric cancer market with its new therapy Perjeta in the pipeline. However, it only targets a minority of patients, who are HER2-positive, which limits sales potential. Overall, GlobalData expects Roche to lose its leading position in the market to Eli Lilly, which owns the recently-approved antiangiogenic agent Cyramza.”
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
